exRNAdisease

General Information

Database ID:

exR0075958

RNA Name:

LASP1

RNA Type:

mRNA

Chromosome:

chr17

Starnd:

Coordinate:

Start Site(bp):

38869859

End Site(bp):

38921770

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABHD14A-ACY1	chr3	51974706	51989183	+
AC007192.1	chr19	18153158	18178117	+
AC010422.3	chr19	12643831	12648397	-
AC010463.1	chr19	17267418	17282966	+
AC073896.1	chr12	56285916	56316059	-
AC093323.1	chr4	6663396	6676755	+
ACTG1	chr17	81509971	81523847	-
ACTR1B	chr2	97655939	97664044	-
ACY1	chr3	51983340	51989197	+
ADAR	chr1	154582057	154628013	-
ADM	chr11	10305073	10307397	+
AGFG2	chr7	100539203	100568220	+
AHCYL1	chr1	109984765	110023742	+
AIF1L	chr9	131096476	131123152	+
AKAP17A	chrX	1591604	1602520	+
AL022238.4	chr22	40346529	40410054	+
AL121845.3	chr20	63708864	63739103	+
AL132780.3	chr14	22946270	22982258	-
AL139011.2	chr1	160216800	160285130	-
ALDH18A1	chr10	95605941	95656711	-
ALDH5A1	chr6	24494867	24537207	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-28-5p	chr3	188688794	188688815	+
hsa-miR-147a	chr9	120244985	120245004	-
hsa-miR-27b-3p	chr9	95085505	95085525	+
hsa-miR-206	chr6	52144401	52144422	+
hsa-miR-342-3p	chr14	100109715	100109737	+
hsa-miR-193b-3p	chr16	14304017	14304038	+
hsa-miR-296-3p	chr20	58817626	58817647	-
hsa-miR-423-5p	chr17	30117095	30117117	+
hsa-miR-873-5p	chr9	28888925	28888945	-
hsa-miR-1224-5p	chr3	184241405	184241423	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC091564.7	chr11	6610883	6616594	-
AC132217.1	chr11	2129121	2129964	-

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference